United States

AstraZeneca PLC (AZN.L)

AZN.L on London Stock Exchange

4:02am EDT
Change (% chg)

-49.00p (-0.98%)
Prev Close
Day's High
Day's Low
Avg. Vol
52-wk High
52-wk Low

Latest Key Developments (Source: Significant Developments)

Astrazeneca says to withdraw EU marketing application for cancer drug
Wednesday, 21 Sep 2016 06:11am EDT 

Astrazeneca Plc : To withdraw marketing authorisation application submitted to European Medicines Agency's Committee for Medicinal Products for Human Use in June 2015 for Cediranib . Says decision to withdraw MAA was based on outstanding questions raised by European Medicines Agency (EMA) . Decision does not affect ongoing primary development programme testing cediranib as a combination treatment .Has not made additional regulatory submissions for cediranib in this indication in any other markets..  Full Article

Astrazeneca says asthma drug shows positive results in phase III trials
Monday, 5 Sep 2016 01:05am EDT 

Astrazeneca Plc : Benralizumab phase III trials show positive results in severe asthma .Respiratory medicine met primary and secondary endpoints in trials for severe asthmaresults from pivotal phase iii trials presented at European Respiratory Society International Congress.  Full Article

Aspen Pharmacare to buy exclusive rights to commercialise AstraZeneca's anaesthetics portfolio
Thursday, 1 Sep 2016 02:00am EDT 

Aspen Pharmacare Holdings Ltd : Had signed an agreement with AstraZeneca whereby AGI will acquire exclusive rights to commercialise astrazeneca's global (excluding USA) anaesthetics portfolio .Transaction was anticipated to complete during Q1 of Aspen's 2017 financial year.  Full Article

Astrazeneca completes Aspen agreement
Thursday, 1 Sep 2016 02:00am EDT 

Astrazeneca Plc : Astrazeneca completes Aspen agreement . Completes commercialisation agreement with Aspen for anaesthetics portfolio .Upfront payment, along with all future milestone and royalty payments, will be reported as externalisation revenue in company's financial statements.  Full Article

AstraZeneca announces results from SYMBICORT study
Wednesday, 31 Aug 2016 05:00pm EDT 

AstraZeneca Plc : SYMBICORT demonstrated comparable risk of serious asthma-related events and lower risk of asthma exacerbations compared to Budesonide alone .Shared results with FDA and will soon be discussing next steps in line with post-marketing requirements.  Full Article

AstraZeneca, Lilly receive FDA fast track designation for AZD3293
Monday, 22 Aug 2016 06:03am EDT 

AstraZeneca Plc :AstraZeneca and Lilly receive FDA fast track designation for AZD3293, an investigational treatment for early Alzheimer'S disease.  Full Article

Lilly and Astrazeneca receive FDA fast track designation for AZD3293
Monday, 22 Aug 2016 06:00am EDT 

Eli Lilly And Co: Lilly and Astrazeneca receive FDA fast track designation for AZD3293, an investigational treatment for early Alzheimer's disease .Also announced planned initiation of a second phase 3 trial for azd3293.  Full Article

Adherium to provide Smartinhalers to Astrazeneca Australia
Tuesday, 16 Aug 2016 07:00am EDT 

Adherium Ltd :Will provide Smartinhalers for an Astrazeneca Australia commercial pilot program in 2016.  Full Article

AstraZeneca says increased Moderna stake to 9 pct
Wednesday, 10 Aug 2016 09:41am EDT 

AstraZeneca Plc : Announced that it has increased its equity interest in Moderna Therapeutics with a $140 mln investment .AstraZeneca's ownership of Moderna will be approximately 9 pct on a fully diluted basis.  Full Article

Hutchison China, AstraZeneca amend savolitinib co-development agreement
Monday, 1 Aug 2016 02:21am EDT 

Hutchison China Meditech : Co and astrazeneca amend co-development agreement to accelerate savolitinib global development program; .Amendment provides that chi-med will contribute up to $50 million, spread primarily over three years.  Full Article

BRIEF-FDA approves Astrazeneca's blood-based companion diagnostic for Tagrisso (osimertinib)

* U.S. FDA has approved a blood-based companion diagnostic for Tagrisso (osimertinib) Source text for Eikon: Further company coverage: